The Cancer Genome Atlas Research Network’s systematic push to comprehensively analyze 33 forms of cancer marks the “end of the beginning” of cancer genomics.
By studying the largest collection yet of prostate cancer samples to be analyzed genomically, researchers have identified genes never before linked to prostate tumors, and started to see patterns that tell localized tumors from metastatic ones.
An analysis of nearly 3,800 colorectal cancer patients — the largest germline risk study for this cancer to date — reveals opportunities for improved risk screening and, possibly, treatment.
Similar mutations in the gene SPOP have completely opposite effects in prostate versus endometrial cancers. What does that mean for efforts aimed at functionally interpreting cancer genetic findings?